GB2175918A - Monoclonal antibodies - Google Patents
Monoclonal antibodies Download PDFInfo
- Publication number
- GB2175918A GB2175918A GB08612160A GB8612160A GB2175918A GB 2175918 A GB2175918 A GB 2175918A GB 08612160 A GB08612160 A GB 08612160A GB 8612160 A GB8612160 A GB 8612160A GB 2175918 A GB2175918 A GB 2175918A
- Authority
- GB
- United Kingdom
- Prior art keywords
- cell
- cell line
- hybridoma
- human primate
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000004027 cell Anatomy 0.000 claims abstract description 104
- 210000004408 hybridoma Anatomy 0.000 claims abstract description 47
- 210000004698 lymphocyte Anatomy 0.000 claims abstract description 21
- 241000288906 Primates Species 0.000 claims abstract description 13
- 241000282693 Cercopithecidae Species 0.000 claims description 18
- 238000000034 method Methods 0.000 claims description 18
- 239000003814 drug Substances 0.000 claims description 12
- 230000004927 fusion Effects 0.000 claims description 12
- 229940079593 drug Drugs 0.000 claims description 11
- 241000282577 Pan troglodytes Species 0.000 claims description 2
- 230000007910 cell fusion Effects 0.000 claims description 2
- 241000894007 species Species 0.000 claims description 2
- 210000000628 antibody-producing cell Anatomy 0.000 claims 9
- 238000003556 assay Methods 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 239000001963 growth medium Substances 0.000 claims 1
- 235000015097 nutrients Nutrition 0.000 claims 1
- 230000035945 sensitivity Effects 0.000 claims 1
- 229960005156 digoxin Drugs 0.000 description 17
- 206010035226 Plasma cell myeloma Diseases 0.000 description 15
- 201000000050 myeloid neoplasm Diseases 0.000 description 15
- LTMHDMANZUZIPE-AMTYYWEZSA-N Digoxin Natural products O([C@H]1[C@H](C)O[C@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@](C)([C@H](O)C4)[C@H](C4=CC(=O)OC4)CC5)CC3)CC2)C[C@@H]1O)[C@H]1O[C@H](C)[C@@H](O[C@H]2O[C@@H](C)[C@H](O)[C@@H](O)C2)[C@@H](O)C1 LTMHDMANZUZIPE-AMTYYWEZSA-N 0.000 description 10
- LTMHDMANZUZIPE-PUGKRICDSA-N digoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)[C@H](O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O LTMHDMANZUZIPE-PUGKRICDSA-N 0.000 description 10
- LTMHDMANZUZIPE-UHFFFAOYSA-N digoxine Natural products C1C(O)C(O)C(C)OC1OC1C(C)OC(OC2C(OC(OC3CC4C(C5C(C6(CCC(C6(C)C(O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)CC2O)C)CC1O LTMHDMANZUZIPE-UHFFFAOYSA-N 0.000 description 10
- 241000699666 Mus <mouse, genus> Species 0.000 description 8
- 108060003951 Immunoglobulin Proteins 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 7
- 102000018358 immunoglobulin Human genes 0.000 description 7
- 239000000427 antigen Substances 0.000 description 6
- 102000036639 antigens Human genes 0.000 description 6
- 108091007433 antigens Proteins 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- 241000282668 Cebus Species 0.000 description 5
- 239000012981 Hank's balanced salt solution Substances 0.000 description 5
- 241000282412 Homo Species 0.000 description 5
- 238000011282 treatment Methods 0.000 description 5
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- LPXQRXLUHJKZIE-UHFFFAOYSA-N 8-azaguanine Chemical compound NC1=NC(O)=C2NN=NC2=N1 LPXQRXLUHJKZIE-UHFFFAOYSA-N 0.000 description 3
- 229960005508 8-azaguanine Drugs 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- 239000006285 cell suspension Substances 0.000 description 3
- 229940072221 immunoglobulins Drugs 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- LPMXVESGRSUGHW-HBYQJFLCSA-N ouabain Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@@H]1C[C@@]2(O)CC[C@H]3[C@@]4(O)CC[C@H](C=5COC(=O)C=5)[C@@]4(C)C[C@@H](O)[C@@H]3[C@@]2(CO)[C@H](O)C1 LPMXVESGRSUGHW-HBYQJFLCSA-N 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000208011 Digitalis Species 0.000 description 2
- WDJUZGPOPHTGOT-OAXVISGBSA-N Digitoxin Natural products O([C@H]1[C@@H](C)O[C@@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@@](C)([C@H](C6=CC(=O)OC6)CC5)CC4)CC3)CC2)C[C@H]1O)[C@H]1O[C@@H](C)[C@H](O[C@H]2O[C@@H](C)[C@@H](O)[C@@H](O)C2)[C@@H](O)C1 WDJUZGPOPHTGOT-OAXVISGBSA-N 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- 241001272567 Hominoidea Species 0.000 description 2
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 2
- 206010070834 Sensitisation Diseases 0.000 description 2
- 229910000831 Steel Inorganic materials 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 229930013930 alkaloid Natural products 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- OBATZBGFDSVCJD-LALPQLPRSA-N deslanoside Chemical compound O([C@H]1[C@@H](O)C[C@@H](O[C@@H]1C)O[C@H]1[C@@H](O)C[C@@H](O[C@@H]1C)O[C@H]1[C@@H](O)C[C@@H](O[C@@H]1C)O[C@@H]1C[C@@H]2[C@]([C@@H]3[C@H]([C@]4(CC[C@@H]([C@@]4(C)[C@H](O)C3)C=3COC(=O)C=3)O)CC2)(C)CC1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O OBATZBGFDSVCJD-LALPQLPRSA-N 0.000 description 2
- 229960000648 digitoxin Drugs 0.000 description 2
- WDJUZGPOPHTGOT-XUDUSOBPSA-N digitoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)CC5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O WDJUZGPOPHTGOT-XUDUSOBPSA-N 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 210000004754 hybrid cell Anatomy 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 2
- 210000001165 lymph node Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000008313 sensitization Effects 0.000 description 2
- JQWHASGSAFIOCM-UHFFFAOYSA-M sodium periodate Chemical compound [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 description 2
- 210000004989 spleen cell Anatomy 0.000 description 2
- 239000010959 steel Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 229940104230 thymidine Drugs 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 241000282575 Gorilla Species 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 102000018251 Hypoxanthine Phosphoribosyltransferase Human genes 0.000 description 1
- 108010091358 Hypoxanthine Phosphoribosyltransferase Proteins 0.000 description 1
- 241000282567 Macaca fascicularis Species 0.000 description 1
- 241000282560 Macaca mulatta Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241000282579 Pan Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000577979 Peromyscus spicilegus Species 0.000 description 1
- 241000288935 Platyrrhini Species 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- 229920002535 Polyethylene Glycol 1500 Polymers 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 239000003855 balanced salt solution Substances 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 210000003917 human chromosome Anatomy 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 238000009177 immunoglobulin therapy Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 238000005360 mashing Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 238000009738 saturating Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000010911 splenectomy Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- VUYXVWGKCKTUMF-UHFFFAOYSA-N tetratriacontaethylene glycol monomethyl ether Chemical compound COCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO VUYXVWGKCKTUMF-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
- C12N5/12—Fused cells, e.g. hybridomas
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
- C12N5/12—Fused cells, e.g. hybridomas
- C12N5/16—Animal cells
- C12N5/166—Animal cells resulting from interspecies fusion
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- General Engineering & Computer Science (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Abstract
Non-human primate monoclonal antibodies are prepared from cell lines prepared from a xenogeneic hybridoma and a lymphocyte.
Description
SPECIFICATION
Monoclonal antibodies
The present invention concerns non-human primate monoclonal antibodies, hybridoma cell lines and methods for producing them, as well as the use of said cell lines for producing said antibodies.
Hybridomas are cells formed by the fusion of an immortalizing cell, such as a myeloma cell, to a what is often a non-transformed partner cell usually chosen for its ability to produce a particular, predetermined substance (e.g., a lymphocyte cell to produce antibodies). The resulting hybrid cell may be selected and cloned to obtain cell lines producing substances having a single structure and/or property. In particular, such hybridomas formed with lymphocytes can be used to produce monoclonal antibodies.
The development of hybridoma technology in recent years has been directed to obtaining cell lines which are both stable and have a high and specific production of a particular substance which it is desired to obtain. There have been various approaches to this problem which because of their historical origin have been largely concentrated in the field of immunoglobulins/ antibodies.
A study of previous activities in this field provides an overview of the types of problems encountered and the various solutions so far attempted.
The original impulse for research into hybrid cell lines producing monoclonal products came from the field of immunobiology, the products being monoclonal antibodies. Conventional antisera usually contain a very large number of antibodies which differ structurally in the antigen binding site, but each bind to the same antigen with a greater or lesser degree of avidity and/or specificity. In addition conventional anti-sera also contain a large number of anti-bodies directed against other antigens and reflecting previous defensive reactions of the host individual from whom the antiserum was obtained. Although for most purposes such "broad" antisera were sufficient it was felt that provision of more specificity and reproducibility would mark a significant advance and provide a scientific tool of tremendous potential, particularly in the field of diagnosis and therapy.
The first and now classical solution was that described by Kohler and Milstein [NATURE, 256, 495-497 (1 975)j who succeeded in fusing pre-immunized mouse spleen cells to "drug" sensitive mouse myeloma cells. The thus immortalized fused cells could be grown in vitro and cloned from the single cell level to produce a homogenous cell population producing a homogenous antibody population (monoclonal antibodies). By selection between the many unique cells and selective recloning it was possible to obtain and grow cells which produce antibodies of the desired antigen specificity.
Mouse antibodies produced in this fashion have proved useful for research and diagnostic purposes and some have even been used therapeutically in humans. It would however involve a considerable advance in human immunoglobulin therapy if human or non-human primate antibodies of similar specificity and reproducibility could be obtained in this way. This would also reduce the danger of sensibilisation. Several approaches to the problem of producing human antibodies in vitro have been tried but have so far been largely unsuccessful. These include:
(i) Transformation of normal human lymphocytes with Epstein-Barr virus (EBV). This method has met with little success as cells of this type require a long and tedious process to become established and are extremely difficult to clone and select.
(ii) Fusion of normal (human) lymphocytes with human myeloma cells. This method represents an obvious analogy to the mouse-mouse hybridoma approach but faces the problem that in the human-system only one myeloma cell line has been made broadly available and this was found to be contaminated with mycoplasma which impedes successful fusions.
(iii) Fusion of normal human lymphocytes to an EBV-transformed human lymphoblastoid B-cell line. Whilst this is probably the most reliable and reproducible method yet described it suffers from the basic in vitro drawback encountered with lymphoblastoid cells: they are extremely difficult to clone and, as they represent an early stage in B-cell differentiation lineage, their capacity to produce and secrete antibodies is about 10 times lower than that of true myelomas.
(iv) Fusion of human lymphocytes to mouse myeloma. This method produces cells with the same excellent in vitro characteristics as the mouse-mouse hybridomas but with the great disadvantage that such hybrids have an inherent genetic instability. One particularly troublesome result of this is that they expel the human chromosome on which the genome for forming the kappa light chain of the immunoglobulin is located.
It was subsequently reported that by using a xenogenic hybridoma cell as parent for further fusion to another cell it is possible to obtain a hybridoma of greatly improved stability. (Ostberg, et al., HYBRIDOMA 2, No. 4, 361, 1983) and that these xenogeneic hybridomas present a more benign environment for the improvement of stability in terms of chromosome loss.
This invention concerns a hybridoma cell line comprising a parent immortalizing cell fused to a xenogeneic partner cell, the resulting immortalizing cell being then fused to a cell capable of producing a non-human primate monoclonal antibody. This latter cell is to be genetically compatible with the said partner cell in the xenogeneic hybridoma. By genetically compatible is meant the characteristic of resembling the related cell as to species and genera of origin such as to avoid significant loss of chromosomes and therefore retain a desirable degree of stability after fusion.
It now appears that preparation and use of non-human primate monoclonal antibodies prepared by such xenogeneic hybridoma fusion technique may prove to be a useful approach to the treatment of humans using monoclonal antibodies and in diagnostic applications. No prior report of preparation or isolation of non-human primate monoclonal antibodies is known.
It is accordingly an object of this invention to provide a method for producing stable cell lines which generate non-human primate monoclonal antibodies useful in the treatment of humans and in diagnostics. It is a further object of this invention to provide immunoglobulins derived from non-human primate lymphocytes which are capable of effective use in humans. The non-human primates included in this aspect of the invention include in essence the apes, e.g., organgutans, gorillas, or chimpanzees, and the monkeys, such as new world monkeys, e.g. cebus monkeys, and old world monkeys, e.g. rhesus monkeys. As between the apes and monkeys, it is clear that for practical purposes, the use of animals small enough to be readily handled in laboratory conditions is preferred but this aspect is intended to cover all non-human primates.
In a particular aspect the xenogeneic hybridoma chosen as an immortalizing cell is a myeloma hybrid which has lost its own ability to produce immunoglobulin. An example of such a xenogeneic hybridoma cell would be that between a myeloma cell and a lymphocyte cell. Examples of suitable myeloma cells are those obtained from mice and rats and will preferably produce no immunoglobulin. These myelomas can themselves be hybrids (e.g. mouse myelomaXmouse lymphocyte) which are in effect myelomas. Such a cell is, e.g., the mouse SP-2 myeloma cell line. This may then be fused to a monkey lymphocyte, for instance, to produce monkey monoclonal antibody.
As described in the HYBRIDOMA 2 paper previously referred to (as well as in corresponding patent applications, e.g. UK Patent Application 2,1 13,715A, published August 10, 1983), the xenogeneic hybridoma used for immortalization is made drug resistant prior to further fusing, and the lymphocyte to which it is fused is obtained preferably after pre-sensitization for improved production of the desired substance. The methods used in drug resistance and pre-sensitization treatments are conventional, as is the process of fusing these cells. Selection of the desired hybrids and cloning are also performed in a conventional manner, as earlier described, and published, e.g. in the references quoted above.
In a particular embodiment according to the present invention, the SP-2 cell line is used. It was originally itself a hybridoma between P3-X63-Ag8 line and mouse spleen cells which produce antibodies to sheep red blood cells and has lost its ability to produce antibodies (C.F.
M. Shulmann et al., NATURE 276, 269, 1978).
It is obtainable e.g. from the NIGMS Human Genetic Mutant Cell Repository Ref. GM 35669 A (see US DHHS 1982 Catalog of Cell Lines). This cell line is made drug resistant and then fused with normal human peripheral lymphocytes by conventional techniques [C.F. G. Galfre et al.,
NATURE 266, 550 (1977) and R. Nowinski et al., SCIENCE 210, 537 (1980)].
A large number of hybrids is obtained and, after approximately five weeks, five clones are selected which show fast growth and no antibody production. These cells are selected for resistance to 8-azaguanine and with three of these lines it is possible to obtain mutants which are resistant to 20 ug/ml of 8-azaguanine. These cells are at the same time sensitive to
Hypoxanthine-Aminopterin-Thymidine (HAT) medium which showed that they had lost their ability to produce hypoxanthine phosphoribosyl transferase. One of these lines is SPAZ 4 which may be used for further fusion to obtain the antibody producing hybridoma.
The simple hybridoma cell lines of this invention which produce non-human primate monoclonal antibodies may also, if desired or required, be fused further, such as with a further lymphocyte cell from a monkey, to provide cells of either still greater stability or somewhat different desired characteristics.
The antibodies according to the invention may then be used in humans to fight infectious diseases, malignancies, allergies, and may be used to curb transplantation rejections and for other purposes known in the art, such as in toxicity caused by pharmaceuticals, e.g. digoxin.
They may also be used in diagonostic applications such as kits and the like.
Examples of the types of cell lines to which this invention relates are cell lines comprising mouse myeloma cells and human and non-human primate cells, such as from a mouse-human xenogeneic cell to produce a (mouseXhuman)Xnon-human primate cell line, e.g. a (mouseXhuman)Xmonkey hybridoma cell line, or a (mouseXnon-human primate)Xnon-human primate cell line, such as a (mouseXmonkey)Xmonkey cell line. Further cell lines provided according to this invention include, e.g. a [(mouseXhuman)Xnon-human primatejXnon-human primate cell line, for instance a [(mouseXhuman)Xcebus monkey]Xcebus monkey cell line, a [(mouseXhuman)Xrhe sus monkey]Xrhesus monkey cell line, a [(mouseXhuman)Xchimpanzee]Xchimpanzee cell line, and a [(mouseXhuman)Xrhesus monkey]Xchimpanzee cell line.
The monoclonal antibodies produced according to the invention may be confectioned and administered in conventional manner for therapeutic application and also got up in conventional kits for diagnostic use.
The following examples illustrate the invention.
Example 1
Digoxin is dissolved in 2 ml of absolute ethanol, and 2 ml of 0.1 molar sodium periodate is added dropwise and the mixture incubated for 45 minutes. Then 60 microliters of ethylene glycol is added. After 5 minutes incubation 50 mg of keyhole limpet hemocyanin (KLH) in 10 ml of water at pH 9.5 is added. When the pH stabilizes at 9.5, 0.3 grams of NaBH4 in 2 ml of water is added. The resulting preparation is dialyzed overnight against saline.
About 4 mg of KLH-digoxin in a volume of 0.5 ml is emulsified together with 0.5 ml of
Freund's complete adjuvant. The emulsion is injected intramuscularly in both thighs of a cebus monkey. Following this first injection, the animal is boosted four times with a similar amount of
KLH-digoxin but this time emulsified in 0.5 ml of Freund's incomplete adjuvant. After this immunization the test bleeding shows that the animal has produced antibodies reacting with digoxin that were able to inactive the toxicity of digoxin in in vitro studies. This is shown by noting that dilutions of monkey serum neutralize the toxic (lethal) effect of digoxin (or its analog oubain) on sensitive human lymphoblastoid cells in cell culture. After resting the animal for two months, another injection of 0.5 ml of KLH-digoxin in saline is given intravenously.
On the third day after the last intravenous injection, cells are removed from the animal for fusion.
a. Blood is removed from a peripheral vein into a syringe containing 50 ,ul heparin solution (10,000 USP units/ml). The blood lymphocytes are purified by gradient centrifugation on a cushion of PERCOLLs (Pharmacia, Inc., Piscataway, N.J.). After centifugation the cells are washed in Hank's balanced salt solution (Gibco Laboratories, Grand Island, N.Y., catalog no. 310-4020, widely available commercially).
b. By using aspetic surgical techniques, lymph nodes are removed from the inguinal area. The lymph nodes are mashed through a fine mesh steel net in order to prepare single cell suspensions. The isolated cells are washed in Hank's balanced salt solutions.
c. Using aspetic surgical techniques, a partial splenectomy is performed on the animal. A single cell suspension is prepared from the spleen fragment by mashing the organ through the fine mesh steel net. This isolated single cell suspension is washed in Hank's balanced salt solution.
Approximately 2X107 isolated lymphocytes are mixed with a similar amount of SPAZ-4 myeloma cells (available according to methods described in the art, such as the HYBRIDOMA 2 reference aforementioned) in serum free medium and pelleted together in a centrifuge at low speed. The cell pellet is treated for one minute with 1.0 ml of 50% PEG-1500 in Hank's balanced salt solution at a pH of 8.0. After one minute incubation at 37"C., one ml. of Hank's balanced salt solution is slowly added. In the following one minute, ten more ml of Hank's solution is added. The cells are recovered by centrifugation and resuspended in 20 ml of
Dulbecco's Modified Eagle Medium (No. 430-2100, Gibco Laboratories) VIROLOGY 8, 396 (1959); VIROLOGY 12, 185 (1960); Tissue Culture Standards Committee, IN VITRO, Vol. 6, No.
2, P. 93, containing 20% fetal bovine serum and using HAT (hypoxanthine-aminopterin-thymidine) as a selection system.
After about three weeks, when good growth is seen in the culture wells, supernatant is removed from the cultures for testing. The testing is performed by an ELISA technique using digoxin coupled to bovine serum albumin (BSA) as the antigen (the BSA-digoxin is produced in a way analogous to the KLH-digoxin). Positive clones are detected using a rabbit anti-human or anti-monkey immunoglobulin-peroxidase system. Positive clones are picked for scaling up and at the same time cloned by limiting dilution in microtiter wells using mouse thymocytes as filler cells. As soon as a large number of cells are available the clones are frozen in liquid nitrogen at 1960C.
Antibodies are produced by growing the hybridoma cell lines either in stationary culture or in roller culture using Dulbecco's MEM with a maximum of 10% fetal bovine serum. Antibodies, typically at a concentration of 20 to 50 micrograms per milliliter, are purified by affinity chromatography on Sepharose Protein A columns (Pharmacia, Inc.), by loading the material to be chromatographed onto the column, saturating the column's binding capacity and washing the column with phosphate buffered saline. After removal of the unbound material from the column, the column is eluted with 0.05 M sodium citrate containing 0.5 M sodium chloride (pH 3.0). The eluate is rapidly neutralized by addition of 1 M Tris-HCI, pH 8.0).
Example 2
Cells produced according to the cell production and selection processes of Example 1, which cells have over time lost their ability to generate immunoglobulin, are made drug resistant by treatment in the presence of 20 g/ml of 8-azaguanine making it possible to use HAT as a selection system in conventional fashion. The resulting cells are then fused to immunized cebus monkey lymphocytes and after treatment again with HAT-medium, positive cell cultures are selected using the same procedures as described in Example 1 above.
According to this procedure, three antibodies have been obtained from fusions using cells from the cebus monkey. The hybridomas are designated 7-1, 11-1 and 11-3 respectively. All three antibodies have been tested for their ability to inhibit the toxicity of digoxin on a human lymphoblastoid cell line, IM-9. When the antibodies were used in a final concentration of 100 ,ug/ml the following result was obtained:
Digoxin dose causing
Addition no damage phosphate 2.9X 10-8M buffered saline
7-1 4.7X10-7M
11-1 9.4X10-7M
11-3 2.3X10 7M
The 7-1 antibody has also been tested for its specificity against other types of digitalis alkaloids.The result of this specificity testing is summarized in the following table:
Drug dose causing
Drug no damage
phosphate
buffered
saline 7-1 oubain 2X10 8M 2X10 8M digitoxin 5.9X10 9M 2.3X10 8M deslanosid 2.3X10 8M 1.9X10 7M
These data taken together show that antibodies produced by this methodology can be protective to the toxic effect of drugs, and that in the case of digitalis alkaloids one antibody can cover two of the drugs used on an out-clinic patient basis (digoxin and digitoxin) and against one parenterally used drug (deslanosid). It has no activity against another parenteral drug (oubain).
Example 3
In a manner similar to that described in Example 1, KLH-digoxin is used as immunogen in an adult male chimpanzee. After a total of five injections of this antigen, given essentially two weeks apart, a final challenge is administered intravenously with 0.5 ml of KLH-digoxin (approximately 4 mg of protein). Blood sample is taken from the animal on the sixth day after the last i.v. injection and, one day after the bleeding, is used for cell fusion with the SPAZ-4 myeloma cell line using the procedure previously outlined. From the sample obtained on day 6, IgC antibody producing hybridomas designated CH 4-14 and CH 4-25 are obtained, having respectively a lambda and a kappa light chain. Characterization of the light chains is obtained by using the reagents against human immunoglobulins in conventional manner. Such reagents give unambiguous results and the reactivity is stronger to anti-human reagents than to anti-monkey reagents prepared against the cynomolgus monkey. Both of these (mouseXhuman)Xchimpanzee antibodies have affinities for digoxin that are distinctly higher than cebus antibody 11-1 mentioned in Example 2 above.
Claims (22)
1. A hybridoma cell line comprising an immortalizing cell fused to a cell producing a nonhuman primate monoclonal antibody, the immortalizing cell comprising a xenogeneic hybridoma cell fused from a parent immortalizing cell and a partner cell, said antibody producing cell being genetically compatible with said partner cell.
2. A hybridoma cell line as claimed in claim 1 wherein said antibody producing cell is of the same genera as the partner cell in the xenogeneic hybridoma cell parent.
3. A hybridoma cell line as claimed in claim 1 wherein said antibody producing cell is of the same species as the partner cell in the xenogeneic hybridoma cell parent.
4. A hybridoma cell line as claimed in claim 2 wherein the cell producing the non-human primate monoclonal antibody is a lymphocyte.
5. A hybridoma cell line as claimed in claim 1 wherein the non-human primate monoclonal antibody is a monkey monoclonal antibody.
6. A hybridoma cell line according to claim 1 wherein the parent immortalizing cell is of the
SP-2 cell line.
7. A method of producing the hybridoma cell line of claim 1 which comprises making a xenogeneic hybridoma cell drug resistant, and fusing this latter cell to a antibody producing cell which is genetically compatible with the partner cell in the xenogeneic hybridoma, and selecting a desired hybrid.
8. A method as claimed in claim 7 wherein selection of a desired hybrid takes place on the basis of lack of sensitivity to HAT and assay for the ability to produce a non-human primate monoclonal antibody.
9. A cell fusion system which comprises a non-human primate monoclonal antibody producing cell and a xenogeneic hybridoma cell fused from an immortalizing cell and a partner cell genetically compatible with said antibody producing cell, in a nutrient culture medium together with an agent which promotes fusion of said cells.
10. Non-human primate monoclonal antibody.
11. An antibody according to claim 10 which is monkey monoclonal antibody.
12. A (mouseXhuman)Xnon-human primate hybridoma cell line.
13. A (mouseXnon-human primate)Xnon-human primate hybridoma cell line.
14. A cell line according to claim 12 which is a (mouseXhuman)Xmonkey hybridoma cell line.
15. A cell line according to claim 13 which is a (mouseXmonkey)Xmonkey hybridoma cell line.
16. A hybridoma cell line comprising a trioma cell fused to a cell producing a non-human primate monoclonal antibody, the trioma cell comprising an immortalizing cell fused to a nonhuman primate lymphocyte, the immortalizing cell comprising a xenogeneic hybridoma cell fused from a parent immortalizing cell and a partner cell, said lymphocyte being genetically compatible with both said partner cell and said antibody producing cell.
17. A hybridoma cell line as claimed in claim 16 wherein said antibody producing cell is of the same genera as the lymphocyte.
18. A hybridoma cell line as claimed in claim 17 wherein the lymophocyte is of the same genera as both the partner cell and said antibody producing cell.
19. A cell line according to claim 16 which is a [(mouseXhuman)Xnon-human primate]Xnonhuman primate cell line.
20. A cell line according to claim 19 which is a [(mouseXhuman)Xchimpanzee]Xchimpanzee cell line.
21. A cell line according to claim 14 which is a (mouseXhuman)Xchimpanzee cell line.
22. An antibody according to claim 10 which is chimpanzee monoclonal antibody.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US73719685A | 1985-05-23 | 1985-05-23 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| GB8612160D0 GB8612160D0 (en) | 1986-06-25 |
| GB2175918A true GB2175918A (en) | 1986-12-10 |
| GB2175918B GB2175918B (en) | 1989-06-28 |
Family
ID=24962960
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GB8612160A Expired GB2175918B (en) | 1985-05-23 | 1986-05-19 | Monoclonal antibodies |
Country Status (22)
| Country | Link |
|---|---|
| JP (2) | JPS61271982A (en) |
| KR (1) | KR900007950B1 (en) |
| AT (1) | AT396936B (en) |
| AU (1) | AU603985B2 (en) |
| BE (1) | BE904811A (en) |
| CH (1) | CH670098B (en) |
| CY (1) | CY1644A (en) |
| DE (1) | DE3616324C2 (en) |
| DK (1) | DK240286A (en) |
| FI (1) | FI93469C (en) |
| FR (1) | FR2587357B1 (en) |
| GB (1) | GB2175918B (en) |
| HK (1) | HK37792A (en) |
| IE (1) | IE59184B1 (en) |
| IL (1) | IL78871A (en) |
| IT (1) | IT1203789B (en) |
| LU (1) | LU86437A1 (en) |
| NL (1) | NL8601263A (en) |
| NZ (1) | NZ216251A (en) |
| SE (1) | SE8602288L (en) |
| SG (1) | SG32392G (en) |
| ZA (1) | ZA863871B (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0349851A3 (en) * | 1988-07-04 | 1990-07-04 | Genetik Mab Srl | N-oma cell lines as means for immortalizing substance producing cells of any animal species |
| EP0876478A4 (en) * | 1994-09-13 | 2002-12-18 | Sandoz Pharmaceuticals Corp | Monoclonal antibody to herpes simplex virus and cell line producing same |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0068763A2 (en) * | 1981-07-01 | 1983-01-05 | Board Of Regents, The University Of Texas System | Recombinant monoclonal antibodies |
| GB2113715A (en) * | 1982-01-22 | 1983-08-10 | Sandoz Ltd | Process for the production of human mono-clonal antibodies |
| EP0134552A2 (en) * | 1983-08-20 | 1985-03-20 | Boehringer Ingelheim Kg | Monoclonal antibody with a high affinity for digoxin |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4381292A (en) * | 1980-11-14 | 1983-04-26 | The Board Of Trustees Of The Leland Stanford Jr. University | Anti-human T-lymphocyte monoclonal antibody |
| US4777245A (en) * | 1984-01-06 | 1988-10-11 | Genelabs Incorporated | Non-human primate monoclonal antibodies and methods |
| US4746612A (en) * | 1984-10-12 | 1988-05-24 | Scripps Clinic & Research Foundation | Aotus interspecies hybridomas and monoclonal receptors produced thereby |
-
1986
- 1986-05-13 CH CH192786A patent/CH670098B/de unknown
- 1986-05-15 DE DE3616324A patent/DE3616324C2/en not_active Expired - Fee Related
- 1986-05-19 GB GB8612160A patent/GB2175918B/en not_active Expired
- 1986-05-20 NL NL8601263A patent/NL8601263A/en not_active Application Discontinuation
- 1986-05-21 AU AU57640/86A patent/AU603985B2/en not_active Ceased
- 1986-05-21 JP JP61114952A patent/JPS61271982A/en active Pending
- 1986-05-21 FI FI862131A patent/FI93469C/en not_active IP Right Cessation
- 1986-05-21 NZ NZ216251A patent/NZ216251A/en unknown
- 1986-05-21 IE IE134786A patent/IE59184B1/en not_active IP Right Cessation
- 1986-05-21 SE SE8602288A patent/SE8602288L/en not_active Application Discontinuation
- 1986-05-21 IL IL78871A patent/IL78871A/en not_active IP Right Cessation
- 1986-05-22 KR KR1019860003999A patent/KR900007950B1/en not_active Expired
- 1986-05-22 AT AT0135886A patent/AT396936B/en not_active IP Right Cessation
- 1986-05-22 DK DK240286A patent/DK240286A/en not_active Application Discontinuation
- 1986-05-23 IT IT48048/86A patent/IT1203789B/en active
- 1986-05-23 BE BE1/011495A patent/BE904811A/en not_active IP Right Cessation
- 1986-05-23 LU LU86437A patent/LU86437A1/en unknown
- 1986-05-23 FR FR868607365A patent/FR2587357B1/en not_active Expired
- 1986-05-23 ZA ZA863871A patent/ZA863871B/en unknown
-
1992
- 1992-03-17 SG SG32392A patent/SG32392G/en unknown
- 1992-05-28 HK HK377/92A patent/HK37792A/en unknown
- 1992-11-06 CY CY1644A patent/CY1644A/en unknown
-
1995
- 1995-07-11 JP JP7197143A patent/JPH0841100A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0068763A2 (en) * | 1981-07-01 | 1983-01-05 | Board Of Regents, The University Of Texas System | Recombinant monoclonal antibodies |
| GB2113715A (en) * | 1982-01-22 | 1983-08-10 | Sandoz Ltd | Process for the production of human mono-clonal antibodies |
| EP0134552A2 (en) * | 1983-08-20 | 1985-03-20 | Boehringer Ingelheim Kg | Monoclonal antibody with a high affinity for digoxin |
Non-Patent Citations (1)
| Title |
|---|
| }HYBRIDOMA} VOL 2 NO 4 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0349851A3 (en) * | 1988-07-04 | 1990-07-04 | Genetik Mab Srl | N-oma cell lines as means for immortalizing substance producing cells of any animal species |
| EP0876478A4 (en) * | 1994-09-13 | 2002-12-18 | Sandoz Pharmaceuticals Corp | Monoclonal antibody to herpes simplex virus and cell line producing same |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4350683A (en) | Antibody production from hybrid cell line | |
| FI83538C (en) | FOERFARANDE FOER PRODUKTION AV EN HYBRIDOMCELLINJE. | |
| US4271145A (en) | Process for producing antibodies to hepatitis virus and cell lines therefor | |
| US4916072A (en) | Process for the formation of human-human hybridoma | |
| US4487833A (en) | Method of preparing hybridomas and of purifying immunogenic materials | |
| US4859595A (en) | Method for preparing rabbit monoclonal antibodies, the cell lines used therein and the antibodies produced thereby | |
| US4772572A (en) | Hybridomas and monoclonal antibodies to human IL-2 | |
| Ball et al. | Isolation and characterization of monoclonal antibodies to (Na++ K+)-ATPase | |
| US6849720B2 (en) | Monoclonal antibodies to the human LDL receptor, their production and use | |
| AU2001241002A1 (en) | Monoclonal antibodies to the human LDL receptor, their production and use | |
| EP0093775A1 (en) | Monoclonal antibodies against brugia malayi | |
| US4792601A (en) | Monoclonal antibody to mullerian inhibiting substance | |
| AU603985B2 (en) | Non-human primate monoclonal antibodies and triomas producing them | |
| WO1983001837A1 (en) | Monoclonal antibodies against schistosoma |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PCNP | Patent ceased through non-payment of renewal fee |
Effective date: 19960519 |